The 2020’s and Regenexx
So where are we headed? Our biggest thrust will be making interventional orthopedics competitive on a level playing field with surgical orthopedics. Meaning, by the end of the 2020s, we expect that we will have widespread insurance coverage for what we do. Making the decision between the interventional orthobiologics route or surgery a real choice for most patients, not something driven by how much they can afford out of pocket. We will continue to support and perform the research to make that happen. In the meantime, we expect to save hundreds of millions for our self-funded health plans and disrupt healthcare in the process.
The upshot? Regenexx had a great 2019 and looks forward to starting the 2020’s as the main disruptor of orthopedic care. We want a future where every patient can choose a less invasive route for their care outside of surgery because both options are covered. Making that happen will require much more research, investment, and resources, but we are committed and have made great strides since we began 15 years ago!